Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Financial Statements and ExhibitsItem 9.01, which was not previously filed with the May 2017 Form 8-K and which is permitted to be filed by amendment no later than 71 calendar days after the date on which the May 2017 Form 8-K was required to be filed. Except as stated in this Explanatory Note, no other information contained in the May 2017 Form 8-K is changed. This Amendment 1 should be read in connection with the Initial Form 8-K and the May 2017 Form 8-K, which provide a more complete description of the Acquisition.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
The audited financial statements of Pelican as of and for the years ended December 31, 2016 and 2015 are filed as Exhibit 99.1 to this Amendment No. 1. The attached audited financial statements of Pelican have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
(b) Pro Forma Financial Information.
The following unaudited pro forma condensed combined financial information of Pelican and Heat are filed as Exhibit 99.2 to this Amendment No. 1 and incorporated herein by reference:
(d) Exhibits.
|
Exhibit No. |
Description |
|
23.1 |
Consent of BDO USA, LLP with respect to the audited financial statements of Pelican |
|
99.1 |
Audited financial statements of Pelican as of and for the years ended December 31, 2016 and 2015 |
|
99.2 |
Unaudited pro forma condensed combined statements of operations for the year ended December 31, 2016 of Pelican and Heat |
HEAT BIOLOGICS, INC. ExhibitEX-23.1 2 htbx_ex23z1.htm AUDITOR’S CONSENT Consent of Independent Auditor EXHIBIT 23.1 Consent of Independent Auditor We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-199274 and No. 333-214868) and Form S-8 (No. 333-193453,…To view the full exhibit click here
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.